Implementation of digitally-supported self-management and pulmonary rehabilitation in people with chronic respiratory disease
Supported Technology-enabled Engagement in Pulmonary rehabilitation and User-driven Personalised self-management (STEP-UP): a mixed methods Type III implementation - effectiveness study
Northern Sydney Local Health District
138 participants
Aug 14, 2025
Interventional
Conditions
Summary
The primary objective of this study is to evaluate the implementation of a digitally supported self-management and pulmonary rehabilitation platform, known as Perx-R, in people with chronic respiratory diseases in real-world clinical settings. This study will be a multi-site, mixed-methods, hybrid type III implementation-effectiveness study. Phase 1 (pre-implementation) will involve clinician engagement in education and completion of surveys and focus groups or interviews to inform development of an implementation support toolkit. Phase 2 (implementation) will involve training of clinicians in how to use the Perx-R program and recruitment of people with chronic respiratory disease to use the digital platform to support their self management (recruited from inpatient settings and outpatient respiratory clinics) or pulmonary rehabilitation program programs (recruited following pulmonary rehabilitation assessment)
Eligibility
Plain Language Summary
Simplified for easier understanding
This is a simplified summary. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intervention: The Perx-R digital platform is a cutting-edge digital therapeutic platform designed to enhance self-management (Perx-R self-management program) or support pulmonary rehabilitation (Perx-R Rehab program) through a mobile application. Participants will have access to Perx R for 6 months. During this period, they may use the app to support their usual self management at home (Perx-R self-management) or to participate in an app based pulmonary rehabilitation program delivered at home or in a hybrid model alongside centre based PR. Participants with chronic respiratory diseases will either self onboard to the Perx R app or be assisted by clinicians during setup. Both Perx R program’s (Perx-R self-management and Perx-R Rehab) provide a personalised schedule (tasks) to support chronic respiratory disease self management, including medication reminders, self management education, including airway clearance techniques, health goals, remote monitoring, and health surveys. For patients using the Perx R Rehab program as part of a pulmonary rehabilitation program, an exercise program, prescribed by the physiotherapist based on the initial assessment will also be added as a “task” to the Perx-R program. Exercise prescriptions will be tailored to each individual based on their initial assessment and will include endurance and resistance training, adjusted to the patient’s baseline capacity and goals. The physiotherapist at the participating site will provide weekly reviews, conducted either in person or via telehealth. These reviews will include discussion of the patient’s symptoms during the previous week, their use of the Perx R app, and their adherence to the prescribed exercise program and discussion regardinf progression of exercises. . The pulmonary rehabilitation physiotherapist will monitor patient progress through a dedicated clinical care portal. Adherence to the Perx-R program tasks in both the Perx-R self-management and Perx-R Rehab programs will be monitored through the Perx data analytics team. There will be two phase to this study: Phase 1: Engagement with clinicians. · Education: Multi-disciplinary clinicians (e.g, medical, nursing, allied health, will receive education about the Perx-R platform. The education will be delivered by a study investigator during a 30-45 min face-to-face presentation with the opportunity for attendee’s to ask questions. · Focus groups and Interviews: Following the education sessions, any clinician who attended will be invited to take part in a focus groups and/or semi-structured interview. Focus groups and Interviews will take place within 30 days of the initial education session and will be structured to discuss their perceptions of the Perx-R program and identify barriers and facilitators to implementing Perx-R in real-world clinical practice. Phase 2 – Implementation • Strategy development: Implementation strategies to support use of Perx-R in clinical settings (e.g., resources, training and clinical champions) will be developed based on Phase 1 findings and provided to clinicians. Prior to commencing intervention delivery, clinicians will receive training on the use of Perx-R. During the training clinicians will be provided with an introduction to Perx-R, an overview of how the Perx-R app works, a live app demonstration, and a demonstration of the Clinician Portal during a 1-hour presentation. Clinicians will be supported during implementation by a site clinical champion and provided with resources and training to support the implementation of the intervention in their clinical settings. • Implementation: Following completion of the training, clinicians will be able to offer the Perx-R self management program, to eligible patients from inpatient settings and outpatient respiratory clinics at Royal North Shore Hospital to support chronic respiratory disease self management. Eligible patients will also be offered access to the Perx-R Rehab program following a pulmonary rehabilitation assessment at the outpatient programs at Royal North Shore Hospital, Hornsby Ku-ring-gai hospital and Mona Vale Community Health Centre. Recruitment sites (e.g., inpatient settings, outpatient clinics, and pulmonary rehabilitation programs) will be activated using a stepped-wedge approach, allowing insights gained from early implementation sites to inform and improve implementation at subsequent sites.
Locations(3)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12626000197336